Exhibit 10.17

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

3rd AMENDMENT TO RESEARCH, COLLABORATION AND LICENSE AGREEMENT

 

This THIRD AMENDMENT (“Third Amendment”) is entered into as of October 30, 2017
(the “Third Amendment Effective Date”) by and between Dimension Therapeutics
Inc., having its principal offices at 840 Memorial Drive, Cambridge, MA 02139
(“Licensee”), and The Trustees of the University of Pennsylvania, a Pennsylvania
nonprofit corporation, with offices located at Penn Center for Innovation, 3160
Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”).  Licensee and
Penn are sometimes hereinafter referred to collectively as the “Parties” and
individually as a “Party.”

 

WHEREAS, the Parties entered into a Research, Collaboration & License Agreement
having an effective date of May 5, 2016 as amended by the First Amendment dated
October 18, 2016 and the Second Amendment Dated December 23, 2016 (collectively
the “Agreement”); and

 

WHEREAS, the Parties wish to amend the Agreement to include additional research
and funding;

 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained
in the Agreement and herein, and intending to be legally bound hereby, the
Parties agree as follows:

 

1.

The Research Plan set forth in Exhibit B of the Agreement is hereby amended to
incorporate the updated tasks and activities listed for 2017 under Schedule A to
this Third Amendment.

 

2.

The Research Program Budget in Exhibit C of the Agreement is hereby amended to
include the research budget and corresponding payment schedule for 2017 as set
forth in Schedule B to this Third Amendment.

 

3.

Section 2.3.1(a) of the Agreement is hereby deleted it in its entirety and
replaced with the following language:

 

“Within [***] days of the Effective Date, Licensee shall pay to Penn an amount
of $[***] for performance of the research and development under the Research
Program for [***].

 

On [***], Licensee shall pay to Penn an amount of $[***] for performance of the
research and development under the Research Program for [***].  

 

On [***], Licensee shall pay to Penn an amount of $[***] for performance of the
research and development under the Research Program for [***].  

 

On [***], Licensee shall pay to Penn an amount of $[***] as detailed in Schedule
B, provided however, that prior to the [***] payment date, Licensee and Penn
shall review the payments made by Licensee during [***] in connection with work
performed under the Research Program through [***].   

 

On [***], Licensee shall pay Penn an amount of [***] for performance of the
research and development under the Research Program for [***].

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 2 of 8

 

[***] after Effective Date of this Third Amendment, Licensee shall pay Penn an
amount of [***], as detailed in Schedule B, for performance of the research and
development under the Research Program for [***].

 

 

4.

This Third Amendment and the Agreement, including all Exhibits, Appendices and
Schedules thereto, contain the entire understanding among the Parties respecting
the subject matter hereof and thereof and supersede any and all prior
agreements, understandings and arrangements whether written or oral among the
Parties with respect to the matters contained in the Agreement and this Third
Amendment.  No amendments, changes, modifications or alterations of the terms
and conditions of this Third Amendment shall be binding upon any Party, unless
in writing and signed by an authorized Representative of each Party.

 

5.

Except as expressly modified by this Amendment, the other terms and conditions
of the Agreement shall remain in full force and effect.

 

6.

This Third Amendment may be executed in counterparts, each of which will be
deemed an original, and all of which together will be deemed to be on and the
same instrument.  A facsimile or a portable document format (PDF) copy of this
Third Amendment, including the signature pages, will be deemed an
original.  Executed signature pages may be transmitted by e-mail transmission.

 

(Signatures on following page)

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 3 of 8

 

 

IN WITNESS WHEREOF the Parties hereto have caused this Second Amendment to be
executed and delivered by their duly authorized representatives as set forth
below.

 

 

Agreed on behalf of:

 

Agreed on behalf of:

 

Dimension Therapeutics Inc.

 

 

The Trustees of the University of

Pennsylvania

 

By: /s/ Mary Thistle

 

By: /s/ John Swartley

(Signature)

 

(Signature)

Name:Mary Thistle

 

Name:  John S. Swartley, Ph.D

 

Title:  Chief Operating Officer

 

 

          Associate Vice Provost for
Title:  Research Managing Director, PCI

 

 

Acknowledged as Read and Understood

by Penn Principal Investigator

 

/s/ James Wilson

(Signature)

Name:Dr. James Wilson

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 4 of 8

 

Schedule A

 

 

UPenn / Dimension Therapeutics

Dimension Sponsored Research Agreement 2017 Amendment 3

 

[***]  

 

Wilson’s Disease Work Plan

 

[***]

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 5 of 8

 

Phenylketonuria Work Plan for 2017

 

[***]

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 6 of 8

 

Citrullinemia Work Plan for 2017

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 7 of 8

 

Schedule B

 

[g201802210545485485979.jpg]

 

 

 

--------------------------------------------------------------------------------

[***] Text Omitted and Filed Separately with the Securities and Exchange
Commission

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

University of Pennsylvania

Page 8 of 8

 

 

Payment Schedule

 

Calendar Year 2017 Payment Schedule

 

Payment Due Date                           Amount of Payment to PennPayment
Status

[***]      [***][***]

 

[***] After Third Amendment

    Effective Date          [***][***]

 

[***] of the Final Report      [***][***]